Search Results
Your search for Matthew Stenger matches 7644 pages
Showing 851 - 900Functional Recovery and Quality of Life in Older Patients Undergoing Colorectal Cancer Surgery
In a study of real-world prospective data—GOSAFE—reported in the Journal of Clinical Oncology, Montroni et al found that the majority of patients aged ≥ 70 years undergoing colorectal cancer surgery showed maintained or improved quality of life and achieved functional recovery during follow-up....
Zanidatamab in HER2-Positive Advanced Biliary Tract Cancer
In the phase IIb HERIZON-BTC-01 trial reported in The Lancet Oncology, James J. Harding, MD, and colleagues found that zanidatamab—a bispecific antibody targeting two distinct HER2 epitopes—showed activity in previously treated patients with HER2-positive advanced biliary tract cancer. Study...
Pirtobrutinib After Covalent BTK Inhibitor Treatment in Relapsed or Refractory CLL/SLL
In the phase I/II BRUIN trial reported in The New England Journal of Medicine, Anthony R. Mato, MD, and colleagues found that the noncovalent (reversible) Bruton’s tyrosine kinase (BTK) inhibitor pirtobrutinib exhibited strong activity in patients with relapsed or refractory chronic lymphocytic...
Intraoperative MRI-Guided vs Aminolevulinic Acid–Guided Resection in Newly Diagnosed Patients With Glioblastoma
In a German trial reported in the Journal of Clinical Oncology, Roder et al found that intraoperative magnetic resonance imaging (MRI)-guided surgery did not improve the rate of complete resection vs fluorescence-guided surgery with aminolevulinic acid (5-ALA) in newly diagnosed patients with...
Prediction of Lung Cancer Mortality With Blood-Based Biomarker Panel and PLCO Risk Model
In a study reported in the Journal of Clinical Oncology, Irajizad et al found that use of a blood-based four-marker protein panel (4MP)—together with the Prostate, Lung, Colorectal, and Ovarian (PLCOm2012) lung cancer risk model—was capable of identifying patients at high risk of lung cancer...
Germline Variants in Colorectal Cancer Susceptibility Genes by Race/Ethnicity in Patients With Early-Onset Colorectal Cancer
In a study reported in the Journal of Clinical Oncology, Seagle et al identified the prevalence of germline colorectal cancer susceptibility gene variants according to race and ethnicity among patients with early-onset colorectal cancer. Study Details The study involved patients aged 15 to 49 years ...
Prevalence of Prior Cancer Among Patients With Newly Diagnosed Cancer
In an analysis of Surveillance, Epidemiology, and End Results (SEER) data reported in a research letter in JAMA Oncology, Caitlin C. Murphy, PhD, MPH, and colleagues found that a substantial proportion of patients diagnosed with an incident cancer in 2019 had a history of prior cancer diagnosis....
Second-Line Trastuzumab, Ramucirumab, and Paclitaxel in Previously Treated Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer
In a Korean phase Ib/II trial reported in the Journal of Clinical Oncology, Kim et al found that trastuzumab combined with ramucirumab and paclitaxel showed activity in the second-line treatment of patients with HER2-positive advanced gastric or gastroesophageal junction cancer whose disease...
Olaparib With Abiraterone and Prednisone or Prednisolone for BRCA-Mutated, Metastatic Castration-Resistant Prostate Cancer
On May 31, 2023, the PARP inhibitor olaparib was approved by the U.S. Food and Drug Administration (FDA) with abiraterone and prednisone or prednisolone for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer, as determined by an FDA-approved companion diagnostic test.1...
Epcoritamab-bysp in Treatment of Relapsed or Refractory B-Cell Lymphomas
On May 19, 2023, epcoritamab-bysp was granted accelerated approval by the U.S. Food and Drug Administration for treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL)–not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two ...
Addition of Tislelizumab to Chemotherapy Improves Survival in Treatment of Metastatic Esophageal Squamous Cell Carcinoma
As reported in The Lancet Oncology by Jianming Xu, MD, of Fifth Medical Center, Chinese PLA General Hospital, Beijing, corresponding author Harry H. Yoon, MD, of the Department of Oncology, Mayo Clinic, Rochester, and colleagues, an interim analysis of the phase III RATIONALE-306 trial has shown...
Intracranial Activity of Adagrasib in Patients With KRAS G12C–Mutated NSCLC and Untreated CNS Metastases
In an analysis reported in the Journal of Clinical Oncology, Negrao et al identified outcomes in the KRYSTAL-1 trial among patients with advanced KRAS G12C–mutated non–small cell lung cancer (NSCLC) who had untreated central nervous system (CNS) metastases at baseline and were treated with...
Cancer Mortality Trends Among U.S. Hispanic Populations From 1999 to 2020
In a cross-sectional study reported in JAMA Oncology, Pompa et al found that overall cancer-specific mortality among U.S. Hispanic populations decreased between 1999 and 2020; however, mortality from some cancer types increased in the populations over this period. Study Details The study used data...
Association of Alcohol Intake With Risk of Early-Onset Colorectal Cancer
In a Korean study reported in the Journal of Clinical Oncology, Jin et al found that increased alcohol intake may be associated with an increased risk of early-onset colorectal cancer. Study Details The study involved data from 5,666,576 individuals aged 20 to 49 years from the Korean National...
First-Line FOLFOXIRI Plus Cetuximab or Bevacizumab in BRAF V600E–Mutant Metastatic Colorectal Cancer
In the German phase II FIRE-4.5 trial reported in the Journal of Clinical Oncology, Stintzing et al found that the addition of cetuximab vs bevacizumab to FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) did not improve objective response rate in the first-line treatment of...
Addition of Neoadjuvant Nivolumab to Platinum-Based Chemotherapy in Stage III NSCLC
In the Spanish phase II NADIM II trial reported in The New England Journal of Medicine, Mariano Provencio, MD, PhD, and colleagues found that the addition of nivolumab to platinum-based chemotherapy improved pathologic complete response (pCR) rates among patients with resectable stage IIIA or IIIB...
Addition of Relacorilant to Nab-paclitaxel in Recurrent, Platinum-Resistant Ovarian Cancer
In a phase II trial reported in the Journal of Clinical Oncology, Nicoletta Colombo, MD, and colleagues found that the selective glucocorticoid receptor modulator relacorilant (given on an intermittent schedule) plus nab-paclitaxel showed benefits vs nab-paclitaxel alone in patients with recurrent, ...
First-Line Systemic Treatment Strategies for Initially Unresectable Colorectal Cancer Liver Metastases
In the Dutch Colorectal Cancer Group phase III CAIRO5 study reported in The Lancet Oncology, Bond et al investigated first-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases. The researchers found that FOLFOXIRI (leucovorin, fluorouracil,...
First-Line Enfortumab Vedotin Plus Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer
As reported in the Journal of Clinical Oncology by O’Donnell et al, findings in a cohort of the phase Ib/II EV-103/KEYNOTE-869 study showed durable responses with first-line enfortumab vedotin-ejfv plus pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial...
Multicancer Early Detection Test in Symptomatic Patients Referred From Primary Care
In a prospective study (SYMPLIFY) reported in The Lancet Oncology, Nicholson et al found that a circulating tumor DNA methylation-based multicancer early detection diagnostic test showed promise in predicting a diagnosis of cancer in symptomatic patients referred from primary care for...
Comparison of Conditioning Treatments in Patients With AML Undergoing HLA-Haploidentical Hematopoietic Stem Cell Transplant
In a Chinese phase III trial reported in the Journal of Clinical Oncology, Ling et al found that conditioning with busulfan/fludarabine resulted in reduced transplantation-related mortality vs busulfan/cyclophosphamide in patients with acute myeloid leukemia (AML) undergoing human leukocyte antigen ...
Posttransplantation Cyclophosphamide-Based GVHD Prophylaxis in Patients With Hematologic Cancers Undergoing Allogeneic HSCT
In the phase III BMT CTN 1703 trial reported in The New England Journal of Medicine, Bolaños‑Meade et al found that posttransplantation cyclophosphamide-based graft-vs-host disease (GVHD) prophylaxis improved GVHD-free, relapse-free survival vs standard prophylaxis in patients with hematologic...
TROP-2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Advanced NSCLC
In a phase I study (TROPION-PanTumor01) reported in the Journal of Clinical Oncology, Shimizu et al described outcomes with the trophoblast cell-surface antigen 2 (TROP-2)-directed antibody-drug conjugate datopotamab deruxtecan at the dose selected for further development in patients with advanced...
Addition of External-Beam Radiation Therapy to Brachytherapy in Intermediate-Risk Prostate Cancer
In the phase III NRG Oncology/RTOG 0232 trial reported in the Journal of Clinical Oncology, Jeff M. Michalski, MD, MBA, FASTRO, and colleagues found no significant benefit in 5-year freedom from disease progression with the addition of external-beam radiation therapy (EBRT) to brachytherapy in...
Long-Term Survival Outcomes With Pembrolizumab vs Ipilimumab in Advanced Melanoma: 7-Year Follow-up of KEYNOTE-006
As reported in the Journal of Clinical Oncology by Caroline Robert, MD, PhD, and colleagues, the 7-year follow-up of the phase III KEYNOTE-006 trial has shown a continued overall survival benefit with pembrolizumab vs ipilimumab in patients with advanced melanoma. The primary analysis of the trial...
Daratumumab Plus Chemotherapy as Induction and Extended Consolidation Therapy for Ultra–High-Risk Multiple Myeloma
In an analysis reported in the Journal of Clinical Oncology, Martin F. Kaiser, MD, and colleagues found that daratumumab plus low-dose cyclophosphamide, lenalidomide, bortezomib, and dexamethasone (Dara-CVRd) used as induction and extended consolidation therapy in newly diagnosed patients with...
Use of Fruquintinib in Treating Refractory Metastatic Colorectal Cancer
In the phase III FRESCO-2 trial reported in The Lancet, Dasari et al found that the VEGFR-1,2,3 inhibitor fruquintinib prolonged survival vs placebo in patients with refractory metastatic colorectal cancer. Study Details In the double-blind trial, 691 patients from sites in 14 countries were...
Amcenestrant vs Standard Endocrine Therapy in ER-Positive, HER2-Negative Advanced Breast Cancer
In the phase II AMEERA-3 trial reported in the Journal of Clinical Oncology, Sara M. Tolaney, MD, MPH, and colleagues found that the selective estrogen receptor degrader amcenestrant did not improve progression-free survival vs physician’s choice of endocrine therapy in patients with estrogen...
Direct Oral Anticoagulants vs Low–Molecular-Weight Heparin in Preventing Recurrent VTE in Patients With Cancer
In the CANVAS study, reported in JAMA, Deb Schrag, MD, FASCO, MPH, and colleagues found that use of direct oral anticoagulants was noninferior to low–molecular-weight heparin in preventing recurrent venous thromboembolism (VTE) in patients with cancer. Study Details In the open-label trial, 671...
Risk-Adapted Neoadjuvant Chemoradiotherapy in Rectal Cancer
A report from the German OCUM study published by Ruppert et al in the Journal of Clinical Oncology details long-term locoregional recurrence outcomes with risk-adapted neoadjuvant chemoradiotherapy plus total mesorectal excision and total mesorectal excision alone in patients with rectal cancer....
T-DXd in HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: DESTINY-Gastric02
In the phase II DESTINY-Gastric02 trial reported in The Lancet Oncology, Eric Van Cutsem, MD, PhD, and colleagues found that fam-trastuzumab deruxtecan-nxki (T-DXd) was active in patients with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a...
Use of Eltrombopag in Low-Risk Myelodysplastic Syndrome With Thrombocytopenia
Interim results of a phase II study (EQOL-MDS) reported in the Journal of Clinical Oncology by Oliva et al showed that eltrombopag, an orally bioavailable small molecule acting as a thrombopoietin receptor agonist, significantly increased the rate of platelet response vs placebo in patients with...
Outcomes With an Anthracycline-Free Treatment Protocol in Favorable-Risk Childhood ALL
In an analysis reported in the Journal of Clinical Oncology, Ariffin et al found noninferior event-free survival with an anthracycline-free vs anthracycline-containing regimen among children with favorable-risk B-cell precursor acute lymphocytic leukemia (ALL) enrolled in two Malaysia-Singapore ALL ...
Pembrolizumab/Olaparib vs Next-Generation Hormonal Agents in Previously Treated Patients With Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer
As reported in the Journal of Clinical Oncology by Emmanuel S. Antonarakis, MD, and colleagues, the phase III KEYLYNK-010 trial has shown no improvement in survival outcomes with pembrolizumab/olaparib vs a next-generation hormonal agent (abiraterone or enzalutamide) in previously treated patients...
Association of Cardiac Substructure Radiation Dose and Risk of Late Cardiac Disease in Survivors of Childhood Cancer
In an analysis from the Childhood Cancer Survivor Study (CCSS) reported in the Journal of Clinical Oncology, Bates et al identified relationships among radiation therapy doses, cardiac substructures, and risk of late-onset cardiac disease in survivors of childhood cancer. Study Details The analysis ...
Role of Chemotherapy in Patients With Nonmetastatic Nasopharyngeal Carcinoma Treated With Radiotherapy
In an updated individual patient data network meta-analysis reported in The Lancet Oncology, Petit et al found that the treatment approach with the highest overall survival benefit among patients with nonmetastatic nasopharyngeal carcinoma treated with radiotherapy was induction chemotherapy with...
Immune Checkpoint Inhibitors Show Promise for People Living With HIV
New research involving people living with HIV treated with immune checkpoint inhibitors has provided valuable insights into the safety and efficacy of immunotherapy in this historically excluded population, according to data published in the Journal of Clinical Oncology.1 The real-world data...
Risk of Intracranial Hemorrhage With Direct Oral Anticoagulants vs Low–Molecular-Weight Heparin in Patients With Glioblastoma and VTE
In a single-institution retrospective cohort study reported in Neuro-Oncology, Reed-Guy et al found that direct oral anticoagulant therapy was associated with a reduced risk of clinically relevant intracranial hemorrhage vs low–molecular-weight heparin in patients with glioblastoma diagnosed with...
Ibrutinib/Venetoclax vs Chlorambucil/Obinutuzumab in Previously Untreated Patients With CLL: Association of MRD With Progression-Free Survival
In an analysis of the phase III GLOW trial reported in the Journal of Clinical Oncology, Talha Munir, MBBS, and colleagues found that fixed-duration ibrutinib/venetoclax produced higher rates of undetectable measurable residual disease (MRD) vs chlorambucil/obinutuzumab in previously untreated...
Dose-Escalated Simultaneous Integrated Boost Radiotherapy for Early-Stage Breast Cancer
In the phase III IMPORT HIGH trial reported in The Lancet, Charlotte E. Coles, FRCR, and colleagues found little difference in ipsilateral breast tumor relapse rates with adjuvant dose-escalated simultaneous integrated boost radiotherapy vs lower-dose sequential boost radiotherapy in patients with...
Surgeon Quality Metrics and Survival After Curative-Intent Surgery for NSCLC
In a study reported in the Journal of Clinical Oncology, Ray et al found that higher surgeon quality (determined by intermediate outcome metrics) was associated with improved overall survival among patients undergoing curative resection for non–small cell lung cancer (NSCLC). The investigators...
Addition of Blinatumomab to Standard Chemotherapy in B-Cell ALL in Low-Risk First Relapse
As reported in the Journal of Clinical Oncology by Hogan et al, the phase III Children’s Oncology Group AALL1331 trial has shown that the addition of blinatumomab to standard chemotherapy improved survival outcomes among younger patients with low-risk B-cell acute lymphoblastic leukemia (ALL) in...
First-Line Nivolumab/Ipilimumab Followed by Nivolumab in a Clinically Diverse Population With Unresectable Stage III or IV Melanoma
In the phase IIIb CheckMate 401 trial reported in the Journal of Clinical Oncology, Reinhard Dummer, MD, and colleagues described outcomes with first-line nivolumab/ipilimumab followed by nivolumab in a clinically diverse population of patients with unresectable stage III or IV melanoma, including...
PET/CT-FDG vs Conventional Staging in Locally Advanced Breast Cancer
In a Canadian study reported in the Journal of Clinical Oncology, Dayes et al found that positron-emission tomography/computed tomography–fluorodeoxyglucose (PET/CT-FDG) improved the detection of distant metastasis vs conventional staging in patients with locally advanced breast cancer. It also...
Late-Onset Memory Impairment in Adult Survivors of Childhood Cancer
In an analysis reported in JAMA Network Open, Phillips et al found that adult survivors of childhood cancer were at an increased risk of new-onset memory impairment vs their siblings. Modifiable factors associated with increased risk of impairment among survivors were identified. Study Details The...
Adjuvant Cisplatin/Gemcitabine vs Cisplatin/Fluorouracil After Chemoradiotherapy for Nasopharyngeal Carcinoma
In a Chinese phase III trial reported in The Lancet Oncology, Liu et al found that adjuvant cisplatin/gemcitabine improved progression-free survival vs cisplatin/fluorouracil following chemoradiotherapy in previously untreated patients with N2 or N3 nasopharyngeal carcinoma. Study Details In the...
Retrospective Analysis of Survival With Surgery in the Treatment of Small Cell Carcinoma of the Cervix
In a retrospective registry study reported in The Lancet Oncology, Chu et al found that receipt of surgery was associated with improved overall survival in patients with small cell carcinoma of the cervix compared to no surgery. Study Details The study involved data from the SEER (Surveillance,...
VISION Trial: Health-Related Quality of Life With the Addition of Lu-177 Vipivotide Tetraxetan to Standard of Care in Patients With Advanced Prostate Cancer
In an analysis from the phase III VISION trial reported in The Lancet Oncology by Karim Fizazi, MD, PhD, and colleagues, the addition of lutetium (Lu-177) vipivotide tetraxetan to standard of care was associated with improved health-related quality of life in patients with prostate-specific...
Global Funding for Cancer Research: 2016–2020
In a study reported in The Lancet Oncology, McIntosh et al identified components of global funding for cancer research—both public and philanthropic—between 2016 and 2020. Study Details The study used data from the UberResearch Dimensions database and Cancer Research UK data on human cancer...
Patient-Reported Outcomes From the PROSPECT Trial: Neoadjuvant FOLFOX vs Chemoradiation for Locally Advanced Rectal Cancer
In an analysis from the PROSPECT trial (Alliance N1048) reported in the Journal of Clinical Oncology, Ethan Basch, MD, MSc, FASCO, and colleagues identified patient-reported outcome patterns among those receiving neoadjuvant FOLFOX (fluorouracil, leucovorin, oxaliplatin) or pelvic chemoradiation...
